1. Lemtrada Article 20 Procedure Assessment Report (31 October 2019, https://www.ema.europa.eu/en/documents/referral/lemtrada-article-20-procedure-measures-minimise-risk-serious-side-effects-multiple-sclerosis_en-0.pdf) combined with personal communication to the authors by Sanofi Genzyme together with data on file (including additional information concerning case 6, received 15 February 2020).
2. Alemtuzumab-induced simultaneous onset of autoimmune haemolytic anaemia, alveolar haemorrhage, nephropathy, and stroke: a case report;Alnahdi;Mult. Scler. Relat. Disord.,2020
3. Alemtuzumab-induced lung injury in multiple sclerosis: learning from adversity in three patients;Bianco;Mult. Scler. Relat. Disord.,2019
4. A case of lung injury resembling diffuse pulmonary hemorrhage after the first administration of alemtuzumab in a patient with multiple sclerosis. Role of the HRCT;Cipolla;Monaldi. Arch. Chest. Dis.,2020
5. ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis;Horisberger;Mult. Scler.,2020